Internal limiting membrane detachment associated with papilloedema following brain metastasis in a child with Ewing sarcoma
https://orcid.org/0000-0001-8990-9365
Dilek Guven
Ozgul Altintas
Abstract
This case report presents initial and follow-up findings of a rare case of bilateral internal limiting membrane (ILM) detachment and sub-ILM hemorrhage in a 7-year-old child with Ewing sarcoma, associated with papilloedema due to a brain metastasis and the use of optical coherence tomography (OCT) in the evaluation and follow-up. The child was diagnosed with Ewing sarcoma and she was referred to the ophthalmology clinic because of blurry vision, anisocoria, and strabismus one week after the operation for brain metastasis. Fundus examination showed bilateral grade IV papilloedema, well-defined dome-shaped area extending towards the optic discs with inferiorly located hemorrhage. OCT revealed bilateral ILM detachment surrounded with a ring-shaped retinal elevation and inferiorly located sub-ILM hemorrhage. On the follow-up examinations OCT showed decrease of height of ILM detachment with resolution of sub-ILM hemorrhage. ILM detachment associated with papilloedema due to a brain metastasis is an exceedingly rare occurrence, making this case particularly significant in understanding ocular manifestations of intracranial pathology. OCT plays a crucial role in diagnosing and monitoring the progression of ILM detachment and associated sub-ILM hemorrhage, offering invaluable insights into the pathophysiology of raised intracranial pressure. Recognizing ocular signs such as papilloedema is critical for early detection of intracranial complications in pediatric patients.
##plugins.themes.bootstrap3.article.details##
Ewing’s sarcoma, papilloedema, internal limiting membrane detachment, sub-ILM hemorrhage, optical coherence tomography
2. Hussain RN, Stappler T, Hiscott P, et al. Histopathological changes and clinical outcomes following intervention for sub-internal limiting membrane haemorrhage. Ophthalmologica. 2020;243(3):217-223. doi: 10.1159/000502442. PMID: 31743895.
3. Kumar V, Chanana B. Sub-internal limiting membrane cavity in anaemic retinopathy evident on spectral domain optical coherence tomography. Clin Exp Optom. 2014 Jan;97(1):80-83. doi: 10.1111/cxo.12032. PMID: 23656561.
4. Venkatesh R, Jayadev C, Sridharan A, et al. Internal limiting membrane detachment in acute central retinal artery occlusion: a novel prognostic sign seen on OCT. Int J Retina Vitreous. 2021 Sep 3;7(1):51. doi: 10.1186/s40942-021-00323-7. PMID: 34479634; PMCID: PMC8418027.
5. Kelly JP, Feldman KW, Weiss A. Optical coherence tomography and visual outcomes in pediatric abusive head trauma. Retin Cases Brief Rep. 2024 Mar 1;18(2):225-229. doi: 10.1097/ICB.0000000000001353. PMID: 36121805
6. Ksiaa I, Ghachem M, Besbes H, et al. Swept-source OCT findings in shaken baby syndrome: case report. BMC Ophthalmol. 2020 Oct 7;20(1):396. doi: 10.1186/s12886-020-01666-9. PMID: 33028244; PMCID: PMC7541327.
7. De Maeyer K, Van Ginderdeuren R, Postelmans L, et al. Sub-inner limiting membrane haemorrhage: causes and treatment with vitrectomy. Br J Ophthalmol. 2007 Jul;91(7):869-72. doi: 10.1136/bjo.2006.109132. PMID: 17229799; PMCID: PMC1955625.
8. Brar AS, Ramachandran S, Takkar B, et al. Characterization of retinal hemorrhages delimited by the internal limiting membrane. Indian J Ophthalmol. 2024 Jan 1;72(Suppl 1):S3-S10. doi: 10.4103/IJO.IJO_266_23. PMID: 38131534; PMCID: PMC10833172.
9. Srinivasan S, Kyle G. Subinternal limiting membrane and subhyaloid haemorrhage in Terson syndrome: the macular 'double ring' sign. Eye (Lond). 2006 Sep;20(9):1099-101. doi: 10.1038/sj.eye.6702134. PMID: 16227979.
10. Attia R, Fitoussi R, Mairot K, et al. Risk factors associated with progression from papilloedema to optic atrohy: results from a cohort of 113 patients. BMJ Open Ophth. 2023 Nov; 8(1):e001375. doi: 10.1136/bmjophth-2023-001375. PMID: 37935563; PMCID: PMC10632874.
11. Goto K, Miki A, Yamashita T, et al. Sectoral analysis of the retinal nerve fiber layer thinning and its association with visual field loss in homonymous hemianopia caused by post-geniculate lesions using spectral-domain optical coherence tomography. Graefes Arch Clin Exp Ophthalmol. 2016 Apr;254(4):745-56. doi: 10.1007/s00417-015-3181-1. PMID: 26446718; PMCID: PMC4799802.
12. Malhotra K, Padungkiatsagul T, Moss HE. Optical coherence tomography use in idiopathic intracranial hypertension. Ann Eye Sci. 2020 Mar;5:7. doi: 10.21037/aes.2019.12.06. PMID: 32405617; PMCID: PMC7220123.
13. Wang JK, Kardon RH, Ledolter J, et al. Peripapillary Retinal Pigment Epithelium Layer Shape Changes From Acetazolamide Treatment in the Idiopathic Intracranial Hypertension Treatment Trial. Invest Ophthalmol Vis Sci. 2017 May 1;58(5):2554-2565. doi: 10.1167/iovs.16-21089. PMID: 28492874; PMCID: PMC5425231.
14. Anand A, Pass A, Urfy MZ, et al. Optical coherence tomography of the optic nerve head detects acute changes in intracranial pressure. J Clin Neurosci. 2016 Jul;29:73-6. doi: 10.1016/j.jocn.2015.12.016. PMID: 26898579.
15. Yang EH, Marmagkiolis K, Balanescu DV, et al. Radiation-Induced Vascular Disease-A State-of-the-Art Review. Front Cardiovasc Med. 2021 Mar 30;8:652761. doi: 10.3389/fcvm.2021.652761. PMID: 33860001; PMCID: PMC8042773.
16. Mizrachi A, Ben-Aharon I, Li H, et al. Chemotherapy-induced acute vascular injury involves intracellular generation of ROS via activation of the acid sphingomyelinase pathway. Cell Signal. 2021 Jun;82:109969. doi: 10.1016/j.cellsig.2021.109969. PMID: 33647448; PMCID: PMC10402763.
17. Ariello LE, Mello LGM, Pimentel SLG, Monteiro MLR. Chorioretinal abnormalities in idiopathic intracranial hypertension: case reports. Int J Retina Vitreous. 2022 Jul 22;8(1):48. doi: 10.1186/s40942-022-00403-2. PMID: 35869502; PMCID: PMC9308292.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Archive of Clinical Cases is protected by copyright and may be used in accordance with copyright and other applicable laws. Content available at www.clinicalcases.eu and our digital applications is intended for personal noncommercial use.
Authors who submit a manuscript for publication in Archive of Clinical Cases agree to the following terms: a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) only after the final version of the manuscript was accepted and published, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). d. It is compulsory that before submission authors ensure that their work was not published in any other medical journals or pending acceptance for publication and that "Archives of Clinical Cases" is the only beneficiary at that moment if their work/case will be accepted by us.
Guidelines for linking to www.clinicalcases.eu a. The main purpose of the site linking to the Archive of Clinical Casess site should be educational. b. Links should be made to the Archive of Clinical Casess home page (www.clinicalcases.eu) or to the articles abstract. c. It is forbidden to use the Archive of Clinical Casess cover by outside organizations unless permission has been granted in advance, notifying our Secretary. d. Material owned by the Archive of Clinical Cases (including the name, logo, cover, and text) may not be used in any manner that may induce the idea or suggest that the Archive of Clinical Cases is in some way recommending a specific company, product or service. e. You must not use or allow others to access or use, all or any part of our Site or the contents and/or applications on it for commercial purposes without our permission. To seek permission to do anything prohibited by or not contained in these TERMS, or which requires our prior consent or agreement, you can contact us.